EXAGEN INC (XGN) Stock Price, Quote, News and Overview
NASDAQ:XGN - Nasdaq - US30068X1037 - Common Stock - Currency: USD
XGN Quote, Performance and Key Statistics
7.12
+0.14 (+2.01%)
The current stock price of XGN is 7.12 USD. In the past month the price increased by 24.04%. In the past year, price increased by 263.27%.
XGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.61 | 337.52B | ||
| AMGN | AMGEN INC | 14.22 | 158.74B | ||
| GILD | GILEAD SCIENCES INC | 14.21 | 136.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.94 | 57.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
| ARGX | ARGENX SE - ADR | 100.5 | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.9 | 29.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.62B | ||
| NTRA | NATERA INC | N/A | 22.58B | ||
| BIIB | BIOGEN INC | 8.26 | 19.14B | ||
| INSM | INSMED INC | N/A | 17.98B |
Related stock screener links
About XGN
Company Profile
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 203 full-time employees. The company went IPO on 2019-09-19. The firm has developed and is commercializing a portfolio of testing products, under its AVISE brand. The company commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
Company Info
EXAGEN INC
1261 Liberty Way
Vista CALIFORNIA 92081 US
CEO: Fortunato Ron Rocca
Employees: 203
Phone: 17605601501
EXAGEN INC / XGN FAQ
What is the stock price of EXAGEN INC today?
The current stock price of XGN is 7.12 USD. The price increased by 2.01% in the last trading session.
What is the ticker symbol for EXAGEN INC stock?
The exchange symbol of EXAGEN INC is XGN and it is listed on the Nasdaq exchange.
On which exchange is XGN stock listed?
XGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EXAGEN INC stock?
10 analysts have analysed XGN and the average price target is 7.91 USD. This implies a price increase of 11.03% is expected in the next year compared to the current price of 7.12. Check the EXAGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EXAGEN INC worth?
EXAGEN INC (XGN) has a market capitalization of 155.22M USD. This makes XGN a Micro Cap stock.
How many employees does EXAGEN INC have?
EXAGEN INC (XGN) currently has 203 employees.
What are the support and resistance levels for EXAGEN INC (XGN) stock?
EXAGEN INC (XGN) has a support level at 6.97 and a resistance level at 7.4. Check the full technical report for a detailed analysis of XGN support and resistance levels.
Is EXAGEN INC (XGN) expected to grow?
The Revenue of EXAGEN INC (XGN) is expected to grow by 18.01% in the next year. Check the estimates tab for more information on the XGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EXAGEN INC (XGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XGN, evaluating the profitability, health, valuation and growth aspects
- EXAGEN INC (XGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EXAGEN INC (XGN) Sales and EPS estimates to see what analysts future expectations are.
- EXAGEN INC (XGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EXAGEN INC (XGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- EXAGEN INC (XGN) Stock Chart to make your own analysis
- EXAGEN INC (XGN) Latest news and press-releases to stay up to date.
Does EXAGEN INC (XGN) stock pay dividends?
XGN does not pay a dividend.
When does EXAGEN INC (XGN) report earnings?
EXAGEN INC (XGN) will report earnings on 2025-08-04, before the market open.
What is the Price/Earnings (PE) ratio of EXAGEN INC (XGN)?
EXAGEN INC (XGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.84).
What is the Short Interest ratio of EXAGEN INC (XGN) stock?
The outstanding short interest for EXAGEN INC (XGN) is 1.03% of its float. Check the ownership tab for more information on the XGN short interest.
XGN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to XGN. When comparing the yearly performance of all stocks, XGN is one of the better performing stocks in the market, outperforming 98.95% of all stocks.
XGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XGN. Both the profitability and financial health of XGN have multiple concerns.
XGN Financial Highlights
Over the last trailing twelve months XGN reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 22.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.48% | ||
| ROE | -242.18% | ||
| Debt/Equity | 2.87 |
XGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to XGN. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 31.25% and a revenue growth 18.01% for XGN